We studied recovery of peripheral blood-and bone marrowderived myeloid progenitor cells (CFU-G,M) in 29 patients who received bone marrow transplants 2 mo to 8.5 yr previously. All patients had normal levels of peripheral blood neutrophils, normal bone marrow cellularity, and a normal myeloid:erythroid ratio. Both peripheral blood-and bone marrow-derived CF-U-G,M were markedly reduced compared with normal controls and bone marrow donors. 15±1/106 vs. 37±4/106 (P < 0.001) and 23±5/2 X 10s vs. 170±21/2 X 105 (P < 0.001)1. Five patients had no detectable CFU-G,M even when 106 bone marrow cells were plated. These abnormalities of CFU-G,M were unrelated to age, sex, diagnosis, conditioning regimen, dose of bone marrow cells transplanted, and presence or absence of-graft-vs.-host disease. Patients who received either autotransplants or transplants from identical twins also had decreased or absent CFU-G,M indicating that allogeneic factors and posttransplant immune suppression with methotrexate or corticosteroids were not major determinants of this abnormality. Co-culture of normal or donor peripheral blood or bone marrow mononuclear cells with recipients peripheral blood or bone marrow mononuclear cells, purified T cells, or serum failed to show any evidence of active CFU-G,M suppression. Furthermore, the abnormality of CFU-GM could not be corrected by the addition of normal syngeneic (donor) hematopoietic cells or serum. Depletion of T-cells from recipient bone marrow by physical techniques resulted in marked increase in CFU-G,M (36±13 vs. 138±36; P < 0.05). The abnormality could be reproduced in vitro by readdition of autologous T cells. In contrast to results with T cell depletion by physical techniques, T cell depletion with a monoclonal anti-T antibody (B7) and complement had no effect. These data indicate that most transplant recipients have a marked abnormality in CFU-G,M when these cells are cultured in vitro. In at least some of these patients, the decreased cloning efficiency of CFU-G,M appears to be mediated by a suppressive effect of autologous T cells.
Bone marrow transplantation is increasingly used to treat patients with aplastic anemia, leukemia, and cancer (1) . In a typical bone marrow transplant, the recipient receives high doses of drugs and total body radiation. In most instances this treatment' is lethal to the recipient's bone marrow cells; the hematopoietic stem cells are irreversibly damaged. It is therefore necessary to rescue the recipient from bone marrow failure by the transplantation of normal hematopoietic stem cells from an homologous leukocytic antigen (HLA)-identical sibling or a genetically identical, monozygotic twin. In some instances cryopreserved autologous bone marrow cells have been used.
The high-dose chemotherapy and radiation used to condition these patients is followed by a rapid decrease in erythrocytes, granulocytes, platelets, and lymphocytes. Pancytopenia persists for 2-3 wk followed by. gradual hematologic recovery; blood counts and bone marrow cellularity usually return to normal within 1 to 2 mo. Detailed analyses of gene markers, including sex chromosomes, erythrocyte antigens and polymorphic erythrocyte and leukocyte isoenzymes, indicate that the posttransplant hematopoietic cells are of donor origin.
Despite the restoration of apparently normal hematopoiesis following successful bone marrow transplantation, we questioned whether the pool of hematopoietic stem cells is fully reconstituted and whether these patients have a normal bone marrow reserve. This question was prompted by our observation of decreased hematologic tolerance to cytotoxic drugs in some transplant recipients. We measured granulocyte-macrophage progenitor cells (CFU-G,M)' in blood and bone marrow of 29 patients at 2 mo-7 yr after successful bone marrow transplantation. We found that CFU-G,M were markedly decreased but that this abnormality could be reversed by the removal of T lymphocytes. These data raise questions about the extent of hematopoietic reconstitution after apparently "successful" bone marrow transplantation.
Methods
Patients. 29 patients who received syngeneic, allogeneic, or autologous bone marrow transplants at University of California at Los Angeles between September 1975 and December 1981 and were alive 2 mo to 8.5 yr after transplantation were selected for study. The clinical details, including diagnosis, source, and dose of the transplanted marrow cells and pretransplant conditioning regimen are summarized in Table I . Median age was 29 yr (range, 17-50 yr). There were 20 males and 9 Pretransplant conditioning consisted of cyclophosphamide (120-200 mg/kg) and total body irradiation (3-10 Gy) (2) . Some patients also received high-dose cytarabine, 6-thioguanine, and daunorubicin.
Allograft recipients received methotrexate 15 mg/M2 on day I posttransplant and 10 mg/M2 on days 3, 6, 11, and weekly to day 102 to prevent or modify graft-vs.-host disease (GVHD). Details of transplantation, antibiotics, blood product transfusions, protected environments, and prevention and treatment of GVHD and interstitial pneumonitis have been reported (4) (5) (6) . Most patients (18; 62%) were studied at a time when they were no longer receiving methotrexate. Patients receiving myelotoxic drugs (excluding methotrexate) or antibiotics were excluded. In patients studied before day + 102, samples were obtained 5-6 d after the preceding dose of methotrexate. Results in these patients did not differ from those observed in autotransplant or twin transplant recipients (who did not receive methotrexate) or from recipients studied after day 102 (when methotrexate had been discontinued). Some patients were receiving intermittent trimethoprim-sulfamethoxazole and folinic acid up to 6 mo posttransplant for prophylaxis against pneumocystis carinii. Samples from these patients were obtained 25 d after the preceding drug dose. No difference was noted in results comparing patients receiving or not receiving trimethoprim-sulfamethoxazole or in patients studied < or .6 mo posttransplant. As an additional precaution we studied CFU-G,M in three nontransplant patients receiving equivalent doses of trimethoprim-sulfamethoxazole; all three had normal levels of peripheral blood and bone marrowderived CFU-G,M.
Two patients, one with AML and one with a mixed cell non-Hodgkins lymphoma (7) , received bone marrow transplants from genetically identical, monozygotic twins. Identity was established by similarity of appearance, history of a single placenta, and identity for dermatoglyphics, erythrocyte and leukocyte isoenzymes (8) . Both patients were conditioned with cyclophosphamide and total body irradiation. The patient with lymphoma also received high doses of vinblastine and doxorubicin. These patients did not receive methotrexate after transplantation.
Two patients with testicular cancer resistant to conventional chemotherapy, received high doses of vinblastine, doxorubicin, cyclophosphamide, or etoposide with or without total body radiation. This was followed by infusion of autologous cryopreserved bone marrow cells. Details of these patients have been reported (7) .
Hematologic determinations. Erythrocyte, leukocyte, and platelet counts were determined by standard techniques using an automated Coulter particle counter (Coulter Electronics, Hialeah, FL). Differential counts of .200 cells were performed on Wright's or Giemsa-stained peripheral blood smears on at least three occasions in all patients within I mo of the CFU-G,M determination.
Bone marrow cellularity was determined by microscopic assessment of bone marrow biopsies. Cellularity was evaluated by two investigators unfamiliar with the patients' clinical course or peripheral blood cell counts. Differential cell counts were performed on .200 cells from bone marrow aspirates and the myeloid/erythroid (M/E) ratio determined.
Cell preparation. Bone marrow samples were obtained from the posterior iliac crest under local anesthesia and mixed in 1,000 U preservative-free heparin. Bone marrow or peripheral blood mononuclear leukocytes were recovered from the saline, Ficoll-Hypaque interface after density centrifugation (9) . Cells were washed, and resuspended in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) with 20% fetal calf serum.
CFU-G,M assay. Bone marrow mononuclear cells (2 X l0s cell/ ml) or peripheral blood mononuclear cells (106/ml) were plated in 0.3% agar in the presence of colony-stimulating activity (CSA) as described (10). CSA was provided either by 106 peripheral blood leukocytes in a feeder layer (I 1) or by the addition to plates of 25 Al conditioned medium from a T lymphoblastoid cell line (12) . Samples from several patients were tested with both sources of CSA with comparable results; these data were thus combined for analysis. Under these conditions, bone marrow cells from 20 healthy adult volunteers form 170±21/2 X 101 (range, 41-368) CFU-G,M derived colonies and peripheral blood cells form 37±4/106 (range, 26-53) CFU-G,M colonies.
In initial experiments using 2 X 10 bone marrow cells/plate, CFU-G,M derived colonies from transplant recipients were undetectable or markedly decreased. Therefore, in subsequent experiments, cells were also plated at a concentration of 106 cells/plate. Plates were incubated at 37°C in a humidified atmosphere of 5-7.5% CO2 in air for 10 d and colonies containing .40 cells were enumerated under a dissecting microscope.
Co-culture. Co-cultures were performed as follows: Bone marrow mononuclear (2 X 10) or peripheral blood mononuclear cells (106) from transplant recipients were co-cultured with an equal number of bone marrow or peripheral blood mononuclear cells from the donor or normal volunteers at 37°C X 60 min. The cells were then plated as described. In some experiments, E rosette-forming cells were depleted from recipient or normal bone marrow samples (before plating). These autologous T cells were readded to the E-depleted bone marrow cell at ratios of 1:5, 1:2, or 1:1 (E+:E-). The reconstituted samples were incubated at 37°C for 60 min and then plated for CFU-G,M. To test the effects of serum on CFU-G,M, 0.1 ml of serum from either the recipient or normals was added to 0.9 ml containing bone marrow or peripheral blood mononuclear cells of the recipient, donor, or normal controls. Cells were incubated at 37°C for 60 min and then plated.
Depletion of E rosette-forming T lymphocytes. Mononuclear cells obtained from bone marrow or peripheral blood were incubated with 5% neuraminidase-treated sheep erythrocytes suspended in fetal calf serum (13) . The cells were then layered on a Ficoll-Hypaque density gradient and centrifuged at 400 g for 30 min. E rosette negative (E-) cells were recovered from the interface, washed, and resuspended in RPMI 1640. To recover E rosette positive cells (E+) devoid of sheep erythrocytes, 9 ml sterilized distilled water was added to the pellet for 10 s; isotonicity was then restored by adding I ml of 10 times phosphate-balanced saline (PBS). The cells were twice washed and resuspended in RPMI 1640 medium. Viability was .90% in most experiments and was frequently >95%. Monoclonal antibody. Mononuclear cells from bone marrow or peripheral blood were incubated with a cytotoxic murine monoclonal antibody, B7, with specificity for the E-rosette receptor on T cells (R. Billing, personal communication). 107 cells/ml were mixed with B7 at a final concentration of 1:50 and incubated at 370C for 30 min in a 16-mm test tube. Normal rabbit serum was added as a source of complement at a final concentration of 1:6 and incubated at 370C for 60 min. Aliquots were removed for assessment of E+ rosette-forming cells and for immunofluorescence. The residual cells were plated for CFU-G,M without washing. In a typical experiment <1% E rosetteforming cells were detected following B7 treatment and <2% reacted with untreated anti-T lymphocyte antibodies Leu 1, Leu 2, Leu 3, by immunofluorescence (14) . Treatment with normal rabbit serum alone had no effect on E+ rosette formation.
Erythrocyte burst-forming unit (BFU-E) assay. Peripheral blood or bone marrow mononuclear cells were isolated as described. The mononuclear cells were suspended in Iscove's medium (Gibco Laboratories) at a concentration of 3 X 106/ml. BFU-E were then assayed in the presence of I U of human urinary erythropoietin as described (15) . Plates were incubated for 14 d in a 5% humidified C02 atmosphere and BFLJ-E (250 cells) were enumerated using an inverted microscope. Statistical analysis. Results of the transplant patients and controls were compared by the Student's t test. Analysis of trends was performed by the Mann-Whitney test (16) .
Results
Peripheral blood and bone marrow cellularity and myeloid:erythroid ratio of the 29 patients are indicated in Table  II . Leukocyte counts were normal in 19, minimally decreased in 4, and low in 5 patients. One patient with chronic GVHD and recurrent bacterial infections had a persistently elevated leukocyte count (16.2 X 109/liter). The percent neutrophils was also normal in most instances, with only four patients with low values. Hemoglobin was normal in 26 patients; 3 patients were anemic with hemoglobin < 10 g/dl. Eleven patients had thrombocytopenia. Bone marrow cellularity ranged from 25 to 60% (median 40%). M/E ratio ranged from 1:1 to 10:1 (median 2:1). One patient had an increased M/E ratio that was normal on repeat testing.
Tests of bone marrow-derived CFU-G,M were performed on 26 occasions: 22 patients were studied once and 4 patients were studied twice (Table III) Bone marrow cells from four recipients without detectable CFU-G,M were plated at a higher concentration of 106/plate. In two, low numbers of CFU-G,M (5 and 11/106) were observed; two others still had no detectable CFU-G,M. The seven recipients without CFU-G,M when cells were plated at interval post transplant are indicated in Fig. 1 . Trend analysis failed to demonstrate any significant correlation of CFU-G,M abnormalities with time during the interval studied. A reduction in peripheral blood CFU-G,M was also noted (Table III) . 30 tests were performed in 20 transplant recipients. Mean CFU-G,M was 5±1/106 cells plated (range, 0-43). This is significantly lower than that detected in normals and transplant donors, 37±4/106 (range, 26-53) (P < 0.001). These data are presented graphically in Fig. 1 . Again, there was no apparent correlation between interval posttransplant and peripheral blood derived CFU-G,M.
Co-cultures of bone marrow or peripheral blood mononuclear cells from the recipient and normal volunteer were performed on four occasions (Table IV) normal peripheral blood or bone marrow cells to amplify otherwise undetectable CFU-G,M was observed under these conditions.
In two experiments, bone marrow mononuclear cells from transplant recipients were co-cultured with comparable cells from their donors. In both instances the CFU-G,M observed was reduced from expected values (Table IV) .
When serum from transplant recipients was added to peripheral blood mononuclear cells from normal individuals or donors (n = 3), no significant increase or decrease in CFU-G,M was detected compared with cultures containing autologous serum (data not shown).
To further investigate the cause of decreased CFU-G,M in transplant recipients, we cultured recipient bone marrow or peripheral blood derived mononuclear cells following depletion of autologous E+ rosette-forming cells. Removal of E+ rosette cells resulted in an increase of bone marrow derived CFU-G,M from 36±13/2 X 105 to 138±36 (0.05 > P > 0.02) (Table  V) . This increase could not be accounted for simply by the removal of cells without CFU-G,M activity since only 15-27% of the initial bone marrow samples formed E+ rosettes. Furthermore, removal of E+ rosette-forming cells from controls resulted in only a modest increase in CFU-G,M (170±21 to 209±48/2 X lO5). This increase was not significant. Similar studies were also performed using recipient peripheral blood mononuclear cells depleted of E+ rosette-forming cells. Again, a trend towards increased CFU-G,M was observed (11±5-25±1 1/106) but this was not significant.
In the next series of experiments, we studied this inhibitory effect of E+ rosette-forming cells from transplant recipients on bone marrow CFU-G,M by readdition of autologous E+ rosette- forming cells to E-depleted samples before plating. E+ rosette forming cells were readded to E-depleted marrow at ratios of 1:5, 1:2, or 1:1, the mixture was incubated for 1 h and then cells were plated for CFU-G,M. Data are summarized in Fig.  2 . As previously indicated removal of E+ rosette-forming cells resulted in an increase in CFU-G,M; readdition of E+ cells resulted in a dose-dependent reduction of CFU-G,M. Similar readdition experiments using normal T-depleted bone marrow mononuclear cells and autologous T cells showed no inhibition. We also studied the effect of T cell depletion on CFU-G,M using a murine monoclonal antibody to the E rosette receptor (B7) rather than physical techniques. Recipient bone marrow cells were treated with B7 and complement and CFU-G,M enumerated. The efficiency to T cell removal was assessed by testing for residual E+ rosette-forming cells, and by indirect immunofluorescence staining using both B7 and 3 unrelated anti-T-antibodies (Leu 1, 2, and 3) reactive with different T cell surface antigens than B7. The latter controls were used to exclude the possibility that B7 treatment might block E+ rosette formation and B7 reactivity in immunofluorescence without cytotoxicity. Under all three experimental conditions, the proportion of either E+ rosette, B7 positive, or Leu 1, 2, or 3 positive cells was <2%. Nevertheless, in contrast to the effects of E+ rosette depletion by physical techniques, antibody treatment had no effect on increasing CFU-G,M (pretreatment, 36±14 vs. posttreatment, 31±7).
Finally, we sought to determine whether this finding of decreased or absent CFU-G,M was specific to the myeloid lineage or affected other hematopoietic stem cells. BFU-E were studied in peripheral blood from 13 normal individuals and 6 recipients. In contrast to the data regarding CFU-G,M, no significant decrease in BFU-E was observed; 152/3 X 10' for controls vs. 155/3 X 10' transplant recipients.
Discussion
Peripheral blood and bone marrow CFU-G,M were absent or markedly reduced in 29 patients studied from 2 mo to 8 yr following apparently successful bone marrow transplantation. Most of these patients had normal levels of circulating neutrophils, normal bone marrow cellularity, and a normal myeloid:erythroid ratio. The reduction in CFU-G,M, was independent of age, sex, underlying diagnosis, conditioning regimen, bone marrow cell dose, and the source of transplanted bone marrow cells. Marked reductions in CFU-G,M were observed in recipients of HLA-identical sibling, genetically identical twin, and autologous bone marrow transplants. The reduction in CFU-G,M was observed as long as 8.5 yr after transplantation and there was no apparent trend to recovery over time.
We studied several potential mechanisms that could account for this disparity between apparently normal granulopoiesis in vivo and markedly decreased or absent CFU-G,M as assayed in vitro. Co-culture of unfractionated or T-enriched recipient peripheral blood or bone marrow mononuclear cells with peripheral blood or bone marrow cells from normal individuals produced no inhibition of normal CFU-G,M. Addition of peripheral bloodor bone marrow-derived mononuclear cells from normals did not reverse the decreased CFU-G,M growth of cells from transplant recipients. Similar results were obtained when serum from recipients was added to CFU-G,M cultures; there was no suppression of normal CFU-G,M growth or correlation of the defect in transplant recipients. However, when recipients (donor-derived) bone marrow cells were cocultured with donor bone marrow cells, a decrease in CFU-G,M was observed. Furthermore, the removal of T cells from recipient bone marrow by physical techniques resulted in an increase in CFU-G,M was also noted with T cell depletion.
The marked increase in bone marrow-derived CFU-G,M (32±14-138±36) following depletion of E+ cells cannot be explained simply by removal of non-CFU-G,M forming cells, since only 15-27% of the bone marrow mononuclear cells were E+. One would thus expect only a modest increase in CFU-G,M compared with the fourfold increase observed. Furthermore no increase in CFU-G,M was observed when bone marrow cells from controls were similarly treated.
Density centrifugation may have differential effects on CFU-G,M recovery from normal vs. transplant recipient bone marrow mononuclear cells independent of any effect of T cell depletion. As indicated, our T cell depletion technique required a second density centrifugation to remove contaminating T cells. To avoid potential comfounding of the results by this gradient-related variable, we also analyzed total CFU-G,M recovery pre-and post-T cell depletion in three transplant recipients. 107 bone marrow mononuclear cells contained 1.76±0.6 X 103 (mean±SEM) CFU-G,M. Recovery of nucleated cells after T depletion was 7.3±0.8 X 106. This fraction contained 4.8±0.6 X 103 CFU-G,M, which is equivalent to a plating efficiency of 160/2 X 101. These data indicate that the increase in CFU-G,M observed following T cell depletion (Table V) is not the result of selective enrichment for CFU-G,M by density centrifugation. These data suggest that these cells actively inhibit CFU-G,M growth in vitro. This observation was further supported by experiments in which readdition of autologous E+ cells to E-depleted mononuclear cells resulted in a dose-dependent decrease in CFU-G,M (Fig. 2) .
We were concerned that data regarding E-depletion and allogeneic co-culture experiments gave disparate findings, i.e., E-depletion resulted in increase CFU-G,M, whereas no inhibition was observed in co-culture experiments. One possible explanation for the desparity is that the suppressive effect of the E+ cells was immunologically specific. In preliminary experiments we co-cultured E+ cells from recipients with Ecells from normals. No inhibition of normal CFU-G,M was observed that confirmed this hypothesis. This is further supported by the data in co-culture experiments utilizing transplant recipients and their donor bone marrow. Following marrow transplantation, the recipients hematopoietic cells are donorderived, genetically identical to the transplant donor. Similar evidence of immunologic restoration of T cell inhibition of hematopoiesis has been reported by others (17, 18) .
In contrast to the results with T cell removal by physical techniques, treatment of marrow cells with a monoclonal antibody (B7) to the E-rosette receptor and complement had no effect on CFU-G,M. The reason for this disparity is unknown but there are several possible explanations. It is possible that these inhibitory T cells need not be viable to interact with CFU-G,M. More likely is the possibility that B7 or the rabbit complement might react either directly with CFU-G,M or with a critical accessory cell needed for CFU-G,M proliferation. Studies to address these questions are in progress.
Data from studies in rodents and dogs receiving bone marrow transplants are consistent with our observations in man of decreased CFU-G,M. For example, Siminovitch et al. (19) reported decreased hematopoietic stem cells (CFU-S) in serially transplanted mice. In secondary transplant recipients, the decrease in CFU-S persisted for up to 50 d; in tertiary recipients the decrease in CFU-S remained depressed indefinitely. Similar data have been reported by others (20, 21) .
Hellman and co-workers demonstrated reduced self-replicative capacity of murine CFU-S following serial marrow transplantation (22) . They suggested an inverse relationship between differentiative capacity and potential for stem cell self-renewal. A similar mechanism has been suggested by Morley and coworkers in busulfan-treated mice (23) . These mice maintain near normal peripheral blood counts and bone marrow cellularity despite marked reductions in committed (CFU-G,M) and pluripotent CFU-S. Based on these data one could hypothesize that after bone marrow transplantation in man there is an increased demand on stem cells for differentiation that takes precedence over the demand for self-renewal leading to progressive stem cell depletion. Boggs and Boggs have suggested that a similar mechanism may be operative in some patients with aplastic anemia (24) . Harrison and Astle (25) described the loss of stem cell repopulating ability following transplantation into lethally irradiated mice in a competitive repopulation assay. They found decreased stem cells levels following transplantation by parabiosis or sublethal irradiation. These data imply that it is not the transplant procedure per se that is responsible for the abnormality. Recently, Raghavachar and co-workers reported a similar prolonged decrease in CFU-G,M in dogs that received autologous bone marrow transplant (26) .
There have been several preliminary reports of decreased CFU-G,M after bone marrow transplantation in man. Haak and co-workers (27) found decreased CFU-G,M in five of six patients studied 23 mo posttransplant including one recipient of a twin transplant (28) . These investigators suggested a proliferative defect in CFU-G,M based on studies of shortterm CFU-G,M proliferation in liquid culture. Messner recently observed decreased CFU-G,M in some transplant recipients (personal communication). In contrast to these studies, Atkinson and co-workers (29), Faille et al. reported normal CFU-G,M in transplant recipients (30) . The number of patients studied was, however, small and most were evaluated .3 mo posttransplant. These investigators also used a different technique to isolate mononuclear cells and expressed their data in terms of CFU-G,M per milliliter rather than plating efficiency as was used herein. The time at which the studies are undertaken may be important since Arnold and co-workers reported normal CFU-G,M in the first 3 mo after transplantation followed by decreased levels (31) . We avoided studying patients in the early posttransplant period because of inherent errors in quantitating CFU-G,M in patients with decreased bone marrow cellularity. In none of these studies was the mechanism for the decrease in CFU-G,M investigated in detail.
Interestingly, other investigators have reported decreased CFU-G,M in patients with hematologic disorders who did not receive bone marrow transplants. For example, Bacigalupo and co-workers (32) found reduced CFU-G,M in eight patients with severe AA who recovered normal or near-normal blood counts and bone marrow cellularity following immune suppression with high-dose corticosteroids and/or antilymphocyte globulin. Recently, Testa reported decreased CFU-G,M in children with ALL who completed 2-3 yr of maintenance chemotherapy and were in hematologic remission with normal blood counts for several years (33) . These patients are of interest since they also appear to have persistent abnormalities of T lymphocyte function. Weiner et al. reported (34) decreased CFU-G,M following intensive chemotherapy of AML. In this instance, the suppression was thought to be related to a macrophagic-like cell. Deschel and co-workers found decreased blood (but not bone marrow) CFU-G,M in patients with acute leukemia in long-term remission (35) .
There are several common features within the spectrum of experimental and clinical settings reported to result in decreased levels of stem cells (CFU-S or CFU-G,M) despite normal levels of peripheral blood cells and normal bone marrow cellularity. In most instances, there has been either damage or stress to the bone marrow followed by gradual recovery of normal or near-normal hematopoiesis. Furthermore, several of these settings including busulfan-treated mice, patients with ALL and AA, and human transplant recipients, are also associated with immune abnormalities. Data indicating normal levels of BFU-E suggest that the defect in CFU-G,M is unlikely to be the result of nonspecific myelotoxicity by drugs given posttransplant such as methotrexate or trimethoprim-cotrimoxazole; a conclusion further supported by demonstration of the CFU-G,M defect in twins and autotransplant recipients.
The data presented herein suggest that the observed decrease in CFU-G,M in transplant recipients resulted, at least in part, from an abnormal in vitro interaction between CFU-G,M and E rosette-forming cells. Whether a similar abnormality is operational in vivo is unknown but is suggested by the increased sensitivity of transplant recipients to cytotoxic chemotherapy. Also unknown whether this abnormal interaction is restricted to CFU-G,M or affects other more primitive granulocyte-macrophage progenitor cells, such as CFU-DG or CFU-GEMM. Other cell lines may also be affected. We and others have reported decreased T lymphocyte progenitor cells (CFU-T) in transplant recipients (34, 36) . It is hoped that a detailed analysis of the cellular mechanism underlying this apparent disparity between hematopoietic recovery and CFU-G,M activity may provide an insight to normal mechanisms of regulation of hematopoiesis.
